What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Dysmenorrhea
- Main trialPhase 3
- “The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.”In the company’s words, NCT05640232 on ClinicalTrials.gov
Other drugs for Primary Dysmenorrhea
- DLBS1442Dexa Medica Group · Phase 2/3
- ElagolixAbbVie · Phase 3
- VipoglanstatGesynta Pharma AB · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Jun 2026 | Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026